Literature DB >> 15600245

TMC-114 (Tibotec).

Amy C Shurtleff1.   

Abstract

Tibotec (formerly Tibotec-Virco) is developing TMC-114 as a potential treatment for HIV-1 infection. In February 2001, TMC-126 was revealed as the series prototype, from which TMC-114 was developed. Because of its improved antiviral and superior pharmacokinetic properties, TMC-114 was selected for clinical development. Phase II trials of TMC-114 are underway.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15600245

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  3 in total

1.  Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.

Authors:  Andrey Yu Kovalevsky; Yunfeng Tie; Fengling Liu; Peter I Boross; Yuan-Fang Wang; Sofiya Leshchenko; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2006-02-23       Impact factor: 7.446

Review 2.  Simplification strategies to reduce antiretroviral drug exposure: progress and prospects.

Authors:  John E McKinnon; John W Mellors; Susan Swindells
Journal:  Antivir Ther       Date:  2009

Review 3.  Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.

Authors:  Sarah M McCabe; Qing Ma; Judianne C Slish; Linda M Catanzaro; Neha Sheth; Robert DiCenzo; Gene D Morse
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.